Hayward, United States
Aqtual, Inc., founded in 2019, is at the forefront of transforming the landscape of precision medicine. Focusing on the biotechnology sector, the company operates within the expansive domains of Biotechnology, Health and Wellness, and Machine Learning. Headquartered in the United States, Aqtual leverages a novel cell-free DNA platform aimed at revolutionizing the treatment and management of chronic diseases and oncology.
The company's slogan, "Advancing Precision Medicine Products in the Costliest Disease Areas through a Novel Cell-Free DNA Platform," encapsulates its mission to bridge the gap between innovative research and tangible healthcare solutions. Aqtual recently secured a $31.00M Series B investment round on 01 July 2025, drawing the attention of distinguished investors such as Genoa Ventures, Bold Capital Partners, Yu Galaxy, Manta Ray Ventures, and the BOLD Longevity Growth Fund. This substantial investment highlights confidence in Aqtual's market potential and innovation in cost-effective treatments for high-burden diseases.
